# 2025-18002: FDA Fights Sneaky Fungus Spreading Through Bodies

2025-18002, Disseminated Coccidioidomycosis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-09-17 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-18002
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-18002
- Title: Disseminated Coccidioidomycosis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 44827
- Published: 2025-09-17
- Effective: unknown
- Comments close: 2025-11-17
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Fights Sneaky Fungus Spreading Through Bodies

## Summary

The FDA just dropped a draft guide to help drug makers create treatments for a serious fungal infection called disseminated coccidioidomycosis. This affects people who get sick from certain fungi, and the guide aims to speed up new medicine development. If you’re in the drug business, now’s the time to check it out and get ready for future approvals and investments!

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Disseminated Coccidioidomycosis: Developing Drugs for Treatment." The purpose of this draft guidance is to assist sponsors in the clinical development of drugs for the treatment of disseminated coccidioidomycosis caused by Coccidioides species (i.e., C. immitis and C. posadasii).

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-18002 on federalregister.gov](https://www.federalregister.gov/documents/2025/09/17/2025-18002/disseminated-coccidioidomycosis-developing-drugs-for-treatment-draft-guidance-for-industry)
- [2025-18002 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-09-17/pdf/2025-18002.pdf)

## Related
- [Previous: 2025-18001, Erosive Esophagitis: Developing Drugs for Treatment; Draft Guidance for Industr…](https://policyrisk.com/federal-register/2025-18001)
- [Next: 2025-18003, Center for Scientific Review; Notice of Closed Meetings](https://policyrisk.com/federal-register/2025-18003)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-18002 (as of 2026-06-08).
